Sonpavde, G. P., Valderrama, B. P., Chamie, K., Gupta, S., Santis, M. D., Banerjee, J. K., Ojalvo, L., Ren, Y., Bavle, A., Powles, T. (2025). Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps893